The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bortezomib in KRAS G12D mutant lung cancers.
 
Anna Maria Litvak
No Relationships to Disclose
 
Alexander E. Drilon
Honoraria - Exelixis; Genentech/Roche; Ignyta
Consulting or Advisory Role - Exelixis; Genentech/Roche
Speakers' Bureau - Ignyta
Research Funding - Foundation Medicine
Travel, Accommodations, Expenses - Exelixis; Genentech/Roche; Ignyta
 
Natasha Rekhtman
No Relationships to Disclose
 
Maria Catherine Pietanza
No Relationships to Disclose
 
Jamie E. Chaft
Honoraria - Dava Oncology
Consulting or Advisory Role - Biodesix; Genentech/Roche; Myriad Genetics; Otsuka
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Kaitlin Woo
No Relationships to Disclose
 
Paul K. Paik
Honoraria - Celgene
Consulting or Advisory Role - Celgene; Threshold Pharmaceuticals
Research Funding - AstraZeneca; GlaxoSmithKline
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Exelixis; Genentech/Roche; Novartis; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis